The FDA has approved Amgen’s (NASDAQ:AMGN) expansion of the Kyprolis (carfilzomib) prescribing information to include its use in combination with Darzalex (daratumumab) plus dexamethasone (DKd) in two dosing regimens — once weekly and twice weekly — for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who have received one to three previous lines of therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.